title: [Primary diffuse large B-cell lymphosarcoma of the spleen].
abstract: OBJECTIVE
  To investigate characteristics of the course and efficacy of treatment of diffuse large B-cell lymphosarcoma (DLBL) with primary lesion of the spleen.
  
  
  METHODS
  From 1998 to 2006, primary splenic lesion was registered in 15 of 120 patients with DLBL and affected lymph nodes (LN), spleen and Waldeyer's ring. The diagnosis was made according to WHO criteria. Of them 14 patients had splenectomy as the first stage of therapy. The operation was followed with 6 to 8 courses of CHOP-21 (8 patients), 4 courses of R-CHOP-21 and radiotherapy (one patient). One patient received 7 courses of CHOP-21 followed by splenectomy. Because of the presence of several signs of unfavourable prognosis 5 patients under 60 years were given intensive therapy: 4-6 courses of the modified program NHL-BFM-90, 2 of 5 patients received radiotherapy.
  
  
  RESULTS
  All the patients with primary DLBL of the spleen had two and more signs of unfavourable prognosis: elevated concentration of serum LDG, size of the tumor more than 10 cm, high proliferative activity of tumor cells, B-symptoms, severe condition. Seven patients had centroblastic, 8--anaplastic variants of DLBL. Tumor cells in primary DLBL of the spleen had no specific immunophenotype. Complete remission of the disease was achieved in 9 (90%) of 10 patients treated on programs CHOP-21, R-CHOP-21, in 4 of 4 patients on the modified program NHL-BFM-90. Mean follow-up was 39.3 months (from 7 to 103 months).
  
  
  CONCLUSIONS
  For primary DLBL of the spleen characteristic are long-term remissions on first line therapy according to CHOP-21 program irrespective of morphology and immunophenotype.
authors.forename: A U
authors.initials: AU
authors.lastname: Magomedova
authors.forename: S K
authors.initials: SK
authors.lastname: Kravchenko
authors.forename: A M
authors.initials: AM
authors.lastname: Kremenetskaia
authors.forename: I B
authors.initials: IB
authors.lastname: Kaplanskaia
authors.forename: E E
authors.initials: EE
authors.lastname: Zybunova
authors.forename: R S
authors.initials: RS
authors.lastname: Samoĭlova
authors.forename: I A
authors.initials: IA
authors.lastname: Vorob'ev
authors.forename: T N
authors.initials: TN
authors.lastname: Obukhova
authors.forename: V V
authors.initials: VV
authors.lastname: Ryzhko
authors.forename: E E
authors.initials: EE
authors.lastname: Zvonkov
authors.forename: A I
authors.initials: AI
authors.lastname: Vorob'ev
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D003131:Combined Modality Therapy; D003520:Cyclophosphamide; D004317:Doxorubicin; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis* / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone; D011878:Radiotherapy; D012074:Remission Induction; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D016896:Treatment Outcome; D014750:Vincristine